Boehringer-Ingelheim’s Jardiance Approved For Use In India For Adults With Chronic Kidney Disease

The Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority of India, approved Jardiance® (empagliflozin) 10mg tablets as a treatment for adults with chronic kidney disease (CKD) at risk of progression. The drug, manufactured by Boehringer-Ingleheim, is an oral, once-daily, highly selective sodium-glucose cotransporter-2 (SGLT2) inhibitor.

The CDSCO approved the use of Jardiance for adults with eGFR of 30-90 ml/min/1.73m2 to reduce the risk of sustained decline and development of end-stage kidney disease (ESKD) and/or cardiovascular disease. Jardiance is not recommended for consumers with polycystic kidney disease, or consumers . . .